Genmab — Juni 2017
-
PD1 har ikke vist effekt som mono i myelomatose, hvis der er toxicitet i kombi med imid's er det ikke en konkurrent til dara i myelomatose.
-
Så simpelt er det ikke MadsSkjern - alle lægemidler der godkendes i MM som ikke er i kombination med Dara er konkurrenter og vil tage en del af markedet. Sikkert ikke stor men der kommer flere og flere til, så utænkeligt at det ikke samlet set får en betydning. Og antagelserne af Daras samlede salg i MM er jo ikke af ubetydelig størrelse.
-
Aldrig simpelt, men Det vil ikke være en en betydelig konkurrent hvis det ikke kan kombineres med imids
-
@EL - Keytruda not working in MM is good for Genmab. If Merck or Janssen start trials in solid tumors with Keytruda/Darzalex is good for Genmab. Now Keytruda in combo with Pomalyst was so far not safe in MM. But Keytruda has been approved in several solid tumors. So I presume it is safe there. And therefore I hope that Merck or Janssen start trials in solid tumors combining Keytruda and Darzalex. Genmab has nothing to loose. If results are bad = trials stops. If results are good = new market.
-
I hope someone will ask Jan later today in the GS conference about the competitive landscape. I would like to know if he sees Car T technology as competition. I think it is too difficult to produce, too expensive and possibly too toxic. But, like Sukkeralf said above, I assume it will take some market share
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind